Robert Avery is an Ophthalmology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2211 Lomas Blvd NE Fl 1
Albuquerque, NM 871062719
Telephone
505-272-2553Provider last certified this registry record 30 Dec 2024.
Clinical trials
- Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)
Sponsor: California Retina Consultants
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Sponsor: California Retina Consultants
- Analysis of Aqueous and Vitreous Humor
Sponsor: California Retina Consultants
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20254 payments
- ABBVIE INC.Program year20251 payment
- Astellas Pharma US IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
78.7%Prostaglandin Analog32.3%Latanoprost88%Travoprost8%Lumigan4%Part D<11 patientsCorticosteroid19.8%Prednisolone Acetate100%Part D≥150 patients+ 4 more classes in this area
Cardiovascular
14.3%Beta blocker14.3%Timolol Maleate100%Part D≥52 patientsAnti-infectives
4.8%Macrolide3.6%Erythromycin100%Part D<11 patientsTetracycline-class Drug1.2%Doxycycline Hyclate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2010 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”